1BRACAnalysis CDx™ is an in vitro diagnostic device intended for the qualitative detection
and classification of variants in the protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes
using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small insertions
and deletions (indels) are identified by polymerase chain reaction (PCR) and Sanger sequencing. Large deletions and duplications
in BRCA1 and BRCA2 are detected using multiplex PCR. Results of the test are used as an aid in identifying ovarian cancer
patients with deleterious or suspected deleterious germline BRCA variants eligible for treatment with Lynparza™ (olaparib).
This assay is for professional use only and is to be performed only at Myriad Genetic Laboratories, a single laboratory
site located at 320 Wakara Way, Salt Lake City, UT 84108.
The Science Recent Publications
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Myriad myPlan™ Lung Cancer measures
expression levels of critical cell cycle genes. Combined with pathologic
tumor stage, the result is correlated with the 5-year risk of lung cancer
death—guiding physicians in making
chemotherapy decisions for early-stage patients.
Myriad myPath™ Melanoma is a unique molecular test created specifically for difficult-to-diagnose melanoma cases. By analyzing 23 genes, the test provides valuable additive molecular information unavailable from any other method for a more informed diagnosis.
Prolaris® measures the expression level of genes involved with tumor proliferation, providing physicians with unique additional information about a patient’s prostate cancer prognosis and may be used with other clinical factors - providing valuable insight into treatment planning.
Myriad ResultsNow™ electronically delivers Myriad test results. Easily view your patient’s test results from anywhere there is an internet connection. View from your office, home, on any hand-held device.
Some of your patients may need education and counseling regarding genetic testing for hereditary cancer. You may want to use the Patient Education Tools listed below, a series of patient guides to risk assessment and genetic testing. These educational pieces can guide your discussions with patients on hereditary cancer syndromes and cover key information necessary to obtain informed consent for genetic testing. It may be provided to patients as a summary of their visit. You can order the materials though our Online Order Form.
Myriad, the Myriad logo, MyriadPro, the MyriadPro logo, Myriad myRisk Hereditary Cancer, the Myriad myRisk Hereditary Cancer logo, Myriad myPath Melanoma, the Myriad myPath Melanoma logo, Myriad myPlan Lung Cancer, the Myriad myPlan Lung Cancer logo, BRACAnalysis, the BRACAnalysis logo, COLARIS, the COLARIS logo, COLARIS AP, the COLARIS AP logo, MELARIS, the MELARIS logo, PANEXIA, the PANEXIA logo, Prolaris, the Prolaris logo, ResultsNow, the ResultsNow logo, Myriad Promise, and the Myriad Promise logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.